Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Immunovia

0.05 SEK+52.28 %19/11 17:29
Less than 1K followers

IMMNOV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+52.28 %
-5.75 %
-52.04 %
-60.06 %
-66.74 %
-72.55 %
-92.80 %
-99.80 %
-99.29 %

Immunovia operates in the biotechnology industry and focuses on the development of diagnostic tools for the early detection of cancer. The company's research and development is focused on molecular diagnostics and its products are aimed at healthcare institutions and physicians. The business is global with a strong presence in Europe and North America. Immunovia was founded in 2007 and is headquartered in Lund.

Read more
Market cap
139.62M SEK
Turnover
1.46M SEK
Revenue
685K
EBIT %
-11,735.04 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Clark Kent got there first. Why wouldn’t I, as someone in a risk group, rather take CA19-9, which is even more sensitive? Not to mention the burden caused by false positives (well, that doesn’t bother the test seller, of course). For that $750 price, I would rather get a pancreatic...
9/17/2025, 2:54 PM
2
That is precisely the problem with tests of this kind. If a rare disease like pancreatic cancer is screened, the test should be very accurate to avoid unnecessary false positives. Since the layperson does not understand this and may happily buy the test, there is still that small...
9/17/2025, 7:27 AM
by Clark kent
2
It’s going to be tough. The screening market is dominated by big players like Grail and Guardant Health. The only hope is that someone buys them out.
10/23/2026, 9:43 AM
by Clark kent
1
Immunovia is seeing a sharp rise today for the first time in a while, following good news from the Q4 report. Here is an AI summary: 1. 2025 Financial Statements and Reduced Losses The company published its 2025 financial statements on February 24–25, which were positively received...
2/26/2026, 6:15 PM
by Koomikko
1
In familial cases, the sensitivity is the same 78%, the specificity is a bit better 94%, so the math is still quite unforgiving. If we consider that the prior probability of finding pancreatic cancer at a single point in time around age 50 is 10/100,000, and for someone with a family...
9/17/2025, 2:47 PM
by Clark kent
1
Approximately 1,000 new pancreatic cancer cases are diagnosed daily worldwide. Most of them too late.
9/17/2025, 1:13 PM
by Reissu
1
The test is initially targeted at risk groups. Pancreatic cancer took my father, so I would gladly go for that test even once a year. There are enough people in risk groups in the world, and the company is only worth about 20 million euros so far.
9/17/2025, 9:36 AM
by Reissu
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2027

Annual report '26

Regulatory press release2026-11-19 09:29

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Press release2026-11-16 08:30

Ledande amerikanska patientorganisationer stödjer bred tillgång till tester för tidig upptäckt av bukspottkörtelcancer

Immunovia
Press release2026-11-16 08:30

Leading U.S. patient advocacy groups support broad access to testing for early detection of pancreatic cancer

Immunovia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-11-12 11:30

Nyemissioner.se: Läs om Immunovia som genomför en företrädesemission om 63,4 MSEK

Immunovia
Regulatory press release2026-11-12 09:14

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Regulatory press release2026-11-05 09:31

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Regulatory press release2026-11-04 14:00

Immunovia offentliggör prospekt i samband med företrädesemission

Immunovia
Regulatory press release2026-11-04 14:00

Immunovia publishes prospectus in connection with rights issue

Immunovia
Press release2026-11-03 08:00

Data om Immunovias PancreaSure-test presenteras vid Presidential Plenary Session under CGA-IGC:s årsmöte 2026

Immunovia
Press release2026-11-03 08:00

Data on Immunovia’s PancreaSure test to be presented in Presidential Plenary at CGA-IGC 2026 Annual Meeting

Immunovia
Regulatory press release2026-11-02 09:47

Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ)

Immunovia
Press release2026-11-02 08:32

Investor Studios: Immunovias VD presenterar bolaget, kommersialiseringen och emissionen

Immunovia
Regulatory press release2026-11-02 08:30

Immunovia publicerar Delårsrapport juli-september 2026

Immunovia
Regulatory press release2026-11-02 08:30

Immunovia Publishes Interim Report for July-September 2026

Immunovia
Press release2026-10-30 11:00

Immunovia bjuder in till presentation av Q3-rapport 2026

Immunovia
Press release2026-10-30 11:00

Immunovia invites to the presentation on the Q3 report 2026

Immunovia
Regulatory press release2026-10-29 13:45

Kommuniké från extra bolagsstämma i Immunovia AB (publ)

Immunovia
Regulatory press release2026-10-29 13:45

Bulletin from the extraordinary general meeting in Immunovia AB (publ)

Immunovia
Regulatory press release2026-10-28 20:00

Immunovia offentliggör slutliga villkor i företrädesemission

Immunovia
Regulatory press release2026-10-28 20:00

Immunovia announces final terms of rights issue

Immunovia